The histopathological and molecular features of breast carcinoma with tumour budding—a systematic review and meta-analysis
- 24 July 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 183 (3), 503-514
- https://doi.org/10.1007/s10549-020-05810-3
Abstract
Purpose Tumour budding (TB) is an adverse histological feature in many epithelial cancers. It is thought to represent epithelial–mesenchymal transition, a key step in the metastatic process. The significance of TB in breast carcinoma (BC) remains unclear. The aim of this study is to investigate the relationship between TB and other histological and molecular features of BC. Methods A systematic search was performed to identify studies that compared features of BC based on the presence or absence of high-grade TB. Dichotomous variables were pooled as odds ratios (OR) using the Der Simonian–Laird method. Quality assessment of the included studies was performed using the Newcastle–Ottawa scale (NOS). Results Seven studies with a total of 1040 patients (high-grade TB n = 519, 49.9%; low-grade/absent TB n = 521, 50.1%) were included. A moderate to high risk of bias was noted. The median NOS was 7 (range 6–8). High-grade TB was significantly associated with lymph node metastasis (OR 2.32, 95% c.i. 1.77 to 3.03, P < 0.001) and lymphovascular invasion (OR 3.08, 95% c.i. 2.13 to 4.47, P < 0.001). With regard to molecular subtypes, there was an increased likelihood of high-grade TB in oestrogen (OR 1.66, 95% c.i. 1.21 to 2.29, P = 0.002) and progesterone receptor-positive (OR 1.48, 95% c.i. 1.09 to 2.02, P = 0.01) tumours. In contrast, triple-negative breast cancer had a reduced incidence of high-grade TB (OR 0.46, 95% c.i. 0.30 to 0.72, P = 0.0006). Conclusion High-grade TB is enriched in hormone receptor-positive BC and is associated with known adverse prognostic variables. TB may offer new insights into the metastatic process of BC.Keywords
This publication has 58 references indexed in Scilit:
- Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathwayBreast Cancer Research, 2010
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Gene-Expression Signatures in Breast CancerThe New England Journal of Medicine, 2009
- Origins of breast cancer subtypes and therapeutic implicationsNature Clinical Practice Oncology, 2007
- Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysisBMC Cancer, 2007
- Snail2, a mediator of epithelial-mesenchymal transitions, expressed in progenitor cells of the developing endocrine pancreasGene Expression Patterns, 2007
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986